CoChat
Sign Up
Cited by 1,949Venous Thromboembolism Diagnosis and ManagementBlood Coagulation and Thrombosis MechanismsCerebral Venous Sinus Thrombosis

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Malignancies, Prothrombotic Mutations, and the Risk of Venous Thrombosis

Blom, Jeanet W.·2005·JAMA
DOI 10.1001/jama.293.6.715
Open this paper in CoChat — free account

Abstract

CONTEXT: Venous thrombosis is a common complication in patients with cancer, leading to additional morbidity and compromising quality of life. OBJECTIVE: To identify individuals with cancer with an increased thrombotic risk, evaluating different tumor sites, the presence of distant metastases, and carrier status of prothrombotic mutations. DESIGN, SETTING, AND PATIENTS: A large population-based, case-control (Multiple Environmental and Genetic Assessment [MEGA] of risk factors for venous thrombosis) study of 3220 consecutive patients aged 18 to 70 years, with a first deep venous thrombosis of the leg or pulmonary embolism, between March 1, 1999, and May 31, 2002, at 6 anticoagulation clinics in the Netherlands, and separate 2131 control participants (partners of the patients) reported via a questionnaire on acquired risk factors for venous thrombosis. Three months after discontinuation of the anticoagulant therapy, all patients and controls were interviewed, a blood sample was taken, and DNA was isolated to ascertain the factor V Leiden and prothrombin 20210A mutations. MAIN OUTCOME MEASURE: Risk of venous thrombosis. RESULTS: The overall risk of venous thrombosis was increased 7-fold in patients with a malignancy (odds ratio [OR], 6.7; 95% confidence interval [CI], 5.2-8.6) vs persons without malignancy. Patients with hematological malignancies had the highest risk of venous thrombosis, adjusted for age and sex (adjusted OR, 28.0; 95% CI, 4.0-199.7), followed by lung cancer and gastrointestinal cancer. The risk of venous thrombosis was highest in the first few months after the diagnosis of malignancy (adjusted OR, 53.5; 95% CI, 8.6-334.3). Patients with cancer with distant metastases had a higher risk vs patients without distant metastases (adjusted OR, 19.8; 95% CI, 2.6-149.1). Carriers of the factor V Leiden mutation who also had cancer had a 12-fold increased risk vs individuals without cancer and factor V Leiden (adjusted OR, 12.1; 95% CI, 1.6-88.1). Similar results were indirectly calculated for the prothrombin 20210A mutation in patients with cancer. CONCLUSIONS: Patients with cancer have a highly increased risk of venous thrombosis especially in the first few months after diagnosis and in the presence of distant metastases. Carriers of the factor V Leiden and prothrombin 20210A mutations appear to have an even higher risk.

Overview

Integrity signals

Registry

Crossref · 10.1001/jama.293.6.715

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 26 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Blom, J. W.
Affiliations
Leiden University Medical Center (NL)
Corresponding author
Blom, Jeanet W.
ORCID
Blom, Jeanet W.
Venue
JAMA
Publisher
American Medical Association (AMA)
Published
2005-02-09
Volume
293
Issue
6
Pages
715
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
DOI
10.1001/jama.293.6.715
OpenAlex
W2007086823
Cited by
1,949
References
26
Citations by year
2026: 49 · 2025: 66 · 2024: 96 · 2023: 89 · 2022: 123 · 2021: 124 · 2020: 106 · 2019: 112 · 2018: 121 · 2017: 106 · 2016: 98 · 2015: 122 · 2014: 92 · 2013: 96 · 2012: 100
FWCI
48.38
Type
journal article
Language
en
Open access
closed
Locations
  • JAMA (publishedVersion)
  • PubMed (publishedVersion)
  • University of Twente Research Information (publishedVersion)
  • University of Twente Research Information (submittedVersion)
Topics
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
  • Health Sciences › Medicine › Clinical Neurology › Cerebral Venous Sinus Thrombosis
Keywords
venous thrombosis, cancer-associated thrombosis, prothrombotic mutations, factor V Leiden, deep vein thrombosis, pulmonary embolism, hematologic malignancies, lung cancer, gastrointestinal cancer, distant metastasis, thrombosis risk factors, cancer survivors, anticoagulation clinic, MEGA
MeSH terms
Adult, Aged, Factor V, Female, Humans, Male, Middle Aged, Mutation, Neoplasm Metastasis, Neoplasms, Prothrombin, Pulmonary Embolism, Risk, Case-Control Studies, Venous Thrombosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review